Expertise in
17
conditions

Dr. Charles A. Schiffer

Oncology
University Physician Group
1560 E Maple Rd, 
Troy, MI 
Expertise in
17
conditions
University Physician Group
1560 E Maple Rd, 
Troy, MI 

Overview

Charles Schiffer is an Oncologist practicing medicine in Troy, Michigan.

Dr. Schiffer is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Leukemia, and Hairy Cell Leukemia (HCL).

He is actively involved in clinical research, co-authoring 77 peer reviewed articles and participating in 11 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

University Physician Group
1560 E Maple Rd, Troy, MI 48083
Other Locations
Karmanos Cancer Center
4100 John R St, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Grade B Cell Lymphoma
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Double and Triple Hit Lymphoma, Double Expressor Lymphoma and High-Grade B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Prednisone, Prednisolone, Methylprednisolone, Rituximab, Polatuzumab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride
Study Phase: Phase 2
A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma
A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1/Phase 2
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1 / 2 Study to Evaluate the Safety and Tolerability of Adoptively Transferred Autologous T Cells in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Suspended
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-002 T Cells
Study Phase: Phase 1/Phase 2
A Phase 2 Trial of the Discussion of Cost (DISCO) App as an Intervention to Improve Financial Outcomes in Hematologic Cancer Patients
A Phase 2 Trial of the Discussion of Cost (DISCO) App as an Intervention to Improve Financial Outcomes in Hematologic Cancer Patients
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis
A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis
Enrollment Status: Unknown
Publish Date: January 25, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Dexamethasone, Elotuzumab, Lenalidomide
Study Phase: Phase 2
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Phase I Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.
Enrollment Status: Terminated
Publish Date: December 17, 2020
Intervention Type: Other, Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

77 Total Publications

Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML.
Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML.
Journal: The New England journal of medicine
Published: September 02, 2026
Similar Doctors
Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (12.7 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shirish Gadgeel is an Oncologist practicing medicine in Detroit, Michigan. Dr. Gadgeel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Gadgeel is currently accepting new patients.

Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology | Hematology | Internal Medicine
Expertise in
32
conditions
Dr. Rashmi Chugh
Oncology | Hematology | Internal Medicine
Referral may be required

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception E, 
Ann Arbor, MI 
 (36.1 miles away)
734-647-8902
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rashmi Chugh is a Hematologist and an Oncologist practicing medicine in Ann Arbor, Michigan. Dr. Chugh is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Desmoid Tumor, and Ewing Sarcoma. Dr. Chugh is currently accepting new patients.

Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

Henry Ford Medical Center-Columbus

39450 W Twelve Mile Rd, 
Novi, MI 
 (16.6 miles away)
248-344-6688
Languages Spoken:
English, Arabic, Armenian
See accepted insurances
Accepting New Patients
Offers Telehealth

Philip Philip is an Oncologist practicing medicine in Novi, Michigan. Dr. Philip is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Neuroendocrine Tumor, Liver Embolization, and Pancreatectomy. Dr. Philip is currently accepting new patients.

Frequently Asked Questions about Dr. Charles A. Schiffer

How do I make an appointment with Dr. Charles A. Schiffer?

You can book an appointment with Dr. Charles A. Schiffer by calling their office at 800-527-6266. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Charles A. Schiffer a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Charles A. Schiffer is classified as an Elite expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Charles A. Schiffer specialize in?

While Dr. Charles A. Schiffer is a Oncology, they have specific expertise in Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Charles A. Schiffer participate in research or clinical trials?

Yes. Dr. Charles A. Schiffer has published 77 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Dr. Charles A. Schiffer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Charles A. Schiffer accept my insurance?

Dr. Charles A. Schiffer accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 800-527-6266 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schiffer's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile